Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Allergy immunotherapy Market Trends

ID: MRFR/HC/0988-CR
200 Pages
Nidhi Mandole
August 2019

Allergy Immunotherapy Market Research Report: Size, Share, Trend Analysis By Types (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies), By Patient Type (Pediatric, Adult, Geriatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Allergy immunotherapy Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF

Market Trends

Key Emerging Trends in the Allergy immunotherapy Market

The Allergy Immunotherapy Market reveals high demand and dynamic tendencies which we may attribute to more and more allergy cases both internationally and locally. Allergy immunotherapy or shot is a type of therapeutic intervention aiming at inducing tolerance to allergens. As a result, the patient will be desensitized and prepared to avoid severe hypersensitivity reactions. The market has evolved and stands out because of some common things like progress on allergy that has been seen, improved availability of treatments and offer of personal dosage.

A number of factors are encompassed as drivers of the Allergy Immunotherapy Market and, one of them is that the incidence of allergic conditions increases and is on the rise. Allergy, which is characterized by respiratory allergies such as hay fever and food allergy, has been on the ascent and end up being very prevalent subdivisions of the population and various geographic local. This surge in atopic diseases has brought the active treatment need attended by the market growth which we are currently witnessing. Aiding the real cause of allergies, medical immunotherapy has regained its final upright position compared to the symptomatic treatment.

Technological progressions and ground breaking ideas have become the backbone of market trends in the hydraulics industry. Nowadays, conventional immunotherapy for allergy proposes to give the patient multiple injections of the allergens slightly graded in amount, so that he/she grows accustomed or trained to it. But, these days, technology has been used as a substitute to develop other delivery systems, for example sublingual immunotherapy(SLIT). SLIT is an alternative method where allergen extracts are administered sublingually, leading to smooth and patient-centered processes instead of injections. The potential for new modes of administration is the reason why the market has expanded to also service people who are not sold on the injection options.

Also, and to add, we should state that it is the area of the individualized medicine that has progressed enormously within the allergy immunotherapy (AIT) market. In addition with our growing knowledge about the individual case for allergies and allergy reactions will lead to the adaptation of treatment procedures based on the allergen precision profile of each patient. This approach is intended to improve treatment efficacy and reduce the odds of complications while treating the patient. In short, specific allergy vaccination not only provides a refined and productive health care option but it also belongs to the major trend in medicine i.e. precision medicine.

The market mirrors a phenomenon where the conviction to provide preventive and not-wait treatment become the norm. It is not only the case that when treating allergies, the healthcare providers and the individuals now focus more on finding relief from the symptoms but they also do research in the attempt to address the fundamental causes of the allergy. People are becoming more and more concerned with prolonged symptoms of allergy and they get wary about using medications because of their side effects. Allergy immunotherapy is gaining in popularity because it corrects the switching of the immune system to allergens and is thus more sustainable and provides long-lasting relief compared to conventional therapy.

Author
Author Profile
Nidhi Mandole
Senior Research Analyst

She is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Nidhi is comfortably versed in data centric research backed by healthcare educational background. She leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. Her key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, she showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Allergy Immunotherapy Market as of 2024?

<p>The Allergy Immunotherapy Market was valued at 2.83 USD Billion in 2024.</p>

What is the projected market size for the Allergy Immunotherapy Market by 2035?

<p>The market is projected to reach 7.627 USD Billion by 2035.</p>

What is the expected CAGR for the Allergy Immunotherapy Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the market during the forecast period is 9.43%.</p>

Which segment of the Allergy Immunotherapy Market had the highest valuation in 2024?

<p>In 2024, Sublingual Immunotherapy had the highest valuation at 1.2 USD Billion.</p>

What are the projected values for Subcutaneous Immunotherapy by 2035?

<p>Subcutaneous Immunotherapy is projected to reach 2.25 USD Billion by 2035.</p>

Which product category is expected to grow the most in the Allergy Immunotherapy Market?

<p>Conventional Immunotherapy is anticipated to grow significantly, with a projected value of 3.2 USD Billion by 2035.</p>

What is the market valuation for Allergic Rhinitis in 2024?

<p>Allergic Rhinitis was valued at 1.2 USD Billion in 2024.</p>

How does the market for Adult patients compare to Pediatric patients in 2024?

<p>In 2024, the market for Adult patients was valued at 1.5 USD Billion, compared to 0.85 USD Billion for Pediatric patients.</p>

Which key players are leading the Allergy Immunotherapy Market?

<p>Key players include Allergopharma, Anergis, ALK-Abello, and Merck Group, among others.</p>

What is the projected value for Food Allergies in the Allergy Immunotherapy Market by 2035?

<p>The market for Food Allergies is projected to reach 0.53 USD Billion by 2035.</p>

Market Summary

As per Market Research Future analysis, the Allergy Immunotherapy Market Size was estimated at 2.83 USD Billion in 2024. The Allergy Immunotherapy industry is projected to grow from 3.097 USD Billion in 2025 to 7.627 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 9.43% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Allergy Immunotherapy Market is poised for substantial growth driven by technological advancements and increasing awareness.

  • Technological advancements in treatment are enhancing the efficacy of allergy immunotherapy. North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region. Subcutaneous immunotherapy continues to dominate the market, whereas sublingual immunotherapy is witnessing rapid growth. Rising allergy prevalence and increased investment in allergy research are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 2.83 (USD Billion)
2035 Market Size 7.627 (USD Billion)
CAGR (2025 - 2035) 9.43%
Largest Regional Market Share in 2024 North America

Major Players

<p><a href="https://allergopharma.dermapharm.com/en-en/products/allergen-immunotherapy-ait/">Allergopharma </a>(DE), Anergis (CH), ALK-Abello (DK), Merck Group (DE), Stallergenes Greer (GB), HollisterStier Allergy (US), Circassia Pharmaceuticals (GB), DBV Technologies (FR), Rho (US)</p>

Market Trends

The Allergy Immunotherapy Market is currently experiencing a notable transformation, driven by an increasing prevalence of allergic conditions worldwide which is also contributing to the expansion of the broader allergy treatment market. This rise in allergies has prompted a growing demand for effective treatment options, leading to heightened interest in immunotherapy as a viable solution. The market appears to be evolving with advancements in technology and research, which may enhance the efficacy and safety of immunotherapy treatments. Furthermore, the integration of personalized medicine into allergy management is likely to play a crucial role in shaping future therapeutic approaches. As healthcare providers and patients alike seek more tailored solutions, the Allergy Immunotherapy Market is poised for significant growth. In addition to technological advancements, regulatory support is becoming increasingly evident, as governments and health organizations recognize the importance of addressing allergy-related health issues. This support may facilitate the development and approval of new immunotherapy products, thereby expanding treatment options for patients. Moreover, the rising awareness of allergies and their impact on quality of life is likely to drive patient engagement and adherence to treatment protocols. Overall, the Allergy Immunotherapy Market seems to be on a promising trajectory, with various factors converging to create a dynamic and responsive landscape for allergy management.

Technological Advancements in Treatment

The Allergy Immunotherapy Market is witnessing a surge in innovative treatment modalities, including sublingual and injectable immunotherapies. These advancements may enhance patient compliance and improve therapeutic outcomes, as they offer more convenient administration routes and potentially fewer side effects.

Personalized Medicine Integration

There is a growing trend towards personalized medicine within the Allergy Immunotherapy Market reflecting broader developments in the allergy care market. Tailoring treatments to individual patient profiles could lead to more effective management of allergic conditions, as healthcare providers increasingly focus on genetic and environmental factors influencing patient responses.

Regulatory Support and Development

Regulatory bodies are increasingly recognizing the significance of allergy management, leading to enhanced support for the Allergy Immunotherapy Market. This trend may result in expedited approval processes for new therapies, thereby broadening the range of available treatment options for patients.

Allergy immunotherapy Market Market Drivers

Rising Allergy Prevalence

The Allergy Immunotherapy Market is experiencing growth due to the increasing prevalence of allergic conditions worldwide. Allergies, including allergic rhinitis and asthma, affect millions of individuals, leading to a heightened demand for effective treatment options. Recent estimates suggest that approximately 30% of the global population suffers from some form of allergy, which underscores the urgent need for innovative therapies. This rising incidence is prompting healthcare providers to seek advanced immunotherapy solutions, thereby driving market expansion. Furthermore, the growing awareness of the long-term benefits of immunotherapy over traditional symptomatic treatments is likely to enhance patient adoption rates. As more individuals seek relief from allergy symptoms, the Allergy Immunotherapy Market is poised for significant growth in the coming years.

Growing Awareness and Education

The Allergy Immunotherapy Market is experiencing growth driven by increased awareness and education regarding allergic conditions and their treatments. Public health campaigns and educational initiatives are informing patients about the benefits of immunotherapy, which is often underutilized. As more individuals become aware of the long-term advantages of allergy immunotherapy, such as reduced reliance on medications and improved quality of life, the demand for these treatments is expected to rise. Furthermore, healthcare professionals are increasingly advocating for immunotherapy as a viable treatment option, contributing to a shift in patient perceptions. This growing awareness is likely to play a crucial role in expanding the Allergy Immunotherapy Market as more patients seek effective solutions for their allergies.

Advancements in Immunotherapy Techniques

Technological innovations are playing a pivotal role in shaping the Allergy Immunotherapy Market. Recent advancements in treatment methodologies, such as sublingual immunotherapy and monoclonal antibodies, are enhancing the efficacy and safety profiles of allergy treatments. These innovations are not only improving patient outcomes but also expanding the range of allergens that can be effectively treated. For instance, the introduction of personalized immunotherapy approaches, which tailor treatment based on individual patient profiles, is gaining traction. This shift towards more targeted therapies is expected to attract a broader patient base, thereby propelling market growth. As these advancements continue to evolve, the Allergy Immunotherapy Market is likely to witness a surge in demand for novel treatment options.

Increased Investment in Allergy Research

The Allergy Immunotherapy Market is benefiting from increased investment in allergy research and development. Governments and private entities are recognizing the economic burden associated with allergic diseases, which has led to enhanced funding for innovative treatment solutions. In recent years, research funding has seen a notable uptick, with millions allocated to studies focused on immunotherapy. This financial support is fostering the development of new therapies and improving existing ones, thereby expanding the market landscape. Additionally, collaborations between academic institutions and pharmaceutical companies are becoming more prevalent, further driving innovation in the Allergy Immunotherapy Market. As research continues to advance, the potential for breakthrough therapies is likely to increase, attracting further investment.

Regulatory Support for Innovative Therapies

The Allergy Immunotherapy Market is being positively influenced by regulatory support for innovative therapies. Regulatory agencies are increasingly recognizing the importance of immunotherapy in managing allergic conditions and are streamlining the approval processes for new treatments. This supportive regulatory environment is encouraging pharmaceutical companies to invest in the development of novel immunotherapy products. Recent initiatives aimed at expediting the review of allergy treatments are likely to enhance the availability of new therapies in the market. As regulatory frameworks continue to evolve, the Allergy Immunotherapy Market is expected to benefit from a more favorable landscape for innovation and product launches.

Market Segment Insights

By Type: Subcutaneous Immunotherapy (Largest) vs. Sublingual Immunotherapy (Fastest-Growing)

<p>The Allergy Immunotherapy Market exhibits a diverse landscape with several types of therapies vying for dominance. Among them, Subcutaneous Immunotherapy stands out as the largest segment, capturing the majority of the market share due to its longstanding acceptance and established efficacy. On the other hand, Sublingual Immunotherapy has emerged as a significant competitor, particularly favored by patients for its ease of administration. At the same time, Oral Immunotherapy is gradually gaining traction, though it currently holds a smaller share compared to the more traditional therapies. Growth trends within the Allergy Immunotherapy Market are influenced by several factors, such as rising allergy prevalence and advancing research. The convenience of Sublingual and Oral Immunotherapy is making them increasingly popular, particularly among patients seeking alternatives to traditional methods. Furthermore, regulatory approvals and a growing body of clinical evidence supporting these therapies continue to push their adoption rates, indicating a promising trajectory for the future of the Immunotherapy Market.</p>

<p>Subcutaneous Immunotherapy (Dominant) vs. Sublingual Immunotherapy (Emerging)</p>

<p>Subcutaneous Immunotherapy is considered the dominant player in the Allergy Immunotherapy Market, well-established with numerous clinical trial backing its effectiveness for various allergic conditions. This segment provides comprehensive treatment options, often involving multiple injections over a specified period to achieve desensitization. In contrast, Sublingual Immunotherapy represents the emerging trend, appealing especially to patients who prefer a more convenient, less invasive treatment. Its administration as drops or tablets allows for easier compliance, fostering a growing acceptance among healthcare providers and patients alike. Both segments showcase distinct characteristics catering to diverse patient preferences, making the competition in the market increasingly dynamic.</p>

By Product: Allergen Extracts (Largest) vs. Biologics (Fastest-Growing)

<p>The Allergy Immunotherapy Market is experiencing significant segmentation, with allergen extracts holding the largest market share. This segment has been well-established due to its traditional use in treating various allergies, leading to its dominance in the market. In contrast, biologics, which utilize the body’s immune system to combat allergens, are rapidly emerging as a compelling alternative due to increasing awareness and advancements in technology. Their share is steadily rising as they provide targeted therapies with potentially fewer side effects, appealing to both healthcare providers and patients alike.</p>

<p>Allergen Extracts (Dominant) vs. Biologics (Emerging)</p>

<p>Allergen extracts represent the dominant force within the Allergy Immunotherapy Market. These extracts, derived from a variety of allergens such as pollen, dust mites, and mold, have a long-standing history of efficacy in alleviating allergic reactions. Their proven track record and established use in conventional immunotherapy have solidified their market position. On the other hand, <a href="https://www.marketresearchfuture.com/reports/biologics-market-1339">biologics </a>are an emerging segment characterized by innovative therapies that harness biological processes. With their potential to offer personalized treatment options, biologics are experiencing rapid growth, driven by increasing demand for targeted therapies and advancements in biotechnology. This growth highlights the evolving landscape of allergy treatment, pushing both segments into a competitive but complementary existence.</p>

By Indication: Allergic Rhinitis (Largest) vs. Food Allergies (Fastest-Growing)

<p>In the Allergy Immunotherapy Market, the indications of <a href="https://www.marketresearchfuture.com/reports/allergic-rhinitis-market-1547">Allergic Rhinitis</a>, Allergic Asthma, Atopic Dermatitis, and Food Allergies together constitute a significant part of the overall market landscape. Among these, Allergic Rhinitis holds the largest share, attributed to its prevalence and heightened awareness of treatment options. Following this, Allergic Asthma and Atopic Dermatitis also contribute notably, while Food Allergies represent a growing concern that is increasingly gaining traction within the market.</p>

<p>Allergic Rhinitis (Dominant) vs. Food Allergies (Emerging)</p>

<p>Allergic Rhinitis has emerged as the dominant indication in the Allergy Immunotherapy Market, primarily due to its widespread incidence and the availability of effective treatment options. Patients suffering from Allergic Rhinitis are typically seeking relief from the symptoms associated with seasonal and perennial allergies, driving demand for immunotherapy solutions. In contrast, Food Allergies are considered an emerging segment, reflecting increasing incidences and a rising awareness of dietary-related allergies. The rapid growth in this area can be attributed to factors such as the evolving understanding of food allergens, innovative therapeutic developments, and a growing focus on preventive measures in pediatric populations. Together, these segments illustrate a dynamic landscape within the Allergy Immunotherapy Market.</p>

By Patient Type: Adult (Largest) vs. Pediatric (Fastest-Growing)

<p>In the Allergy Immunotherapy Market, the distribution of patient types reveals that adults represent the largest segment due to their higher susceptibility to allergic reactions and the ongoing prevalence of allergy-related illnesses. This demographic is increasingly seeking effective long-term treatment options, resulting in a significant portion of the market share allocated to adult patients. Conversely, the pediatric segment, though smaller in current market share, is witnessing rapid growth. This increase is mainly attributed to the rising awareness among parents regarding childhood allergies and the importance of early intervention in prevention and treatment. Growth trends indicate a surge in the demand for effective allergy treatments tailored to different age groups. Pediatric patients are emerging as a critical focus area, driven by advancements in formulation and treatment protocols specifically designed for younger populations. The growing prevalence of allergies in children and increased healthcare access are boosting the pediatric immunotherapy segment's expansion, while adult treatments continue to dominate due to established practices and ongoing research to enhance efficacy and safety in this age group.</p>

<p>Adult (Dominant) vs. Pediatric (Emerging)</p>

<p>The Adult segment in the Allergy Immunotherapy Market holds a dominant position, characterized by a well-established understanding of adult allergies and a wide array of treatment options. This segment benefits from extensive clinical research and a variety of immunotherapeutic formulations that target common allergens such as pollen, dust mites, and pet dander. Adults are more likely to recognize and seek treatment for their allergies, leading to a sustained demand for immunotherapy solutions. In contrast, the Pediatric segment is emerging rapidly due to a focus on developing specialized treatments that are safe and effective for younger patients. This segment not only addresses allergy treatment but also emphasizes preventive care, engaging parents in the educational aspect of managing childhood allergies. As a result, this dual approach to treatment gives both segments unique but complementary market positions.</p>

Get more detailed insights about Allergy Immunotherapy Market Research Report - Global Forecast till 2035

Regional Insights

The Allergy Immunotherapy Market is witnessing significant growth across its regional segmentation. In 2024, North America leads the market with a valuation of 2.35 USD Billion, driven by high prevalence rates of allergies and advanced healthcare infrastructure. Europe follows with a substantial valuation of 1.7 USD Billion, fueled by an increasing awareness of allergic conditions and improved diagnostic techniques.

South America, with a market value of 0.4 USD Billion, holds potential due to rising healthcare access in developing countries, while Asia Pacific is valued at 0.9 USD Billion, highlighting the growing demand for allergen-specific treatments in densely populated regions.The Middle East and Africa represent a smaller segment valued at 0.36 USD Billion, yet are emerging markets with increasing focus on allergy treatments. Each region significantly contributes to the Allergy Immunotherapy Market revenue, with North America and Europe dominating due to a combination of high healthcare expenditures and robust Research and Development initiatives.

The overall market growth is influenced by rising allergy incidences and an emphasis on personalized medicine, highlighting opportunities across all regions for future advancements in allergic disease management.

Key Players and Competitive Insights

The Allergy Immunotherapy Market is characterized by growing competition as significant developments in the field of immunotherapy, biotechnology, and pharmaceuticals continue to shape the landscape. Several key players have emerged, driving innovation and expanding their product offerings to cater to a rising number of allergy sufferers worldwide. The market is witnessing an increase in strategic collaborations, partnerships, and mergers as companies seek to enhance their portfolio, broaden their geographic reach, and leverage the expertise of others within the industry. The competitive dynamics are further influenced by the growing awareness of allergy and immunotherapy treatments, leading to the introduction of advanced therapy options that improve patient outcomes and provide therapists with more effective solutions.Novartis has established a prominent position within the Allergy Immunotherapy Market by leveraging its comprehensive portfolio of innovative therapies and a strong global footprint. The company's commitment to research and development has resulted in the introduction of advanced allergy immunotherapy products that address various forms of allergic reactions. A notable strength of Novartis lies in its ability to effectively navigate regulatory landscapes, enabling timely product approvals and market entry in diverse regions. This, combined with robust distribution channels and strategic collaborations, has allowed Novartis to solidify its presence in the allergy immunotherapy space. Their ongoing investment in research and patient engagement initiatives further enhances their standing as a key player in providing meaningful solutions for allergy sufferers worldwide.Hal Allergie is actively involved in the Allergy Immunotherapy Market, offering a range of immunotherapy solutions designed to address different allergic conditions. Their key products include various allergy vaccines and diagnostic tools that cater to specific allergens, enhancing their market presence. Hal Allergie has built a reputation for delivering high-quality allergen immunotherapy treatments, aided by their commitment to innovation and stringent production standards. Their strength in the market is underscored by a solid distribution network and strategic collaborations that facilitate their growth in global regions. The company has also pursued mergers and acquisitions to expand its product portfolio and capabilities, further positioning itself as a reliable provider in the allergy immunotherapy segment. Through these efforts, Hal Allergie aims to maintain its competitive edge and continue contributing to advancements in allergy treatment globally.

Key Companies in the Allergy immunotherapy Market include

Industry Developments

Recent developments in the Allergy Immunotherapy Market have been significant, particularly with advancements in treatment options and company positioning. In October 2023, Aimmune Therapeutics announced promising results from its clinical trials on peanut allergy treatments, further validating the efficacy of immunotherapy. Meanwhile, Novartis has focused on expanding its portfolio in allergy treatments, partnering with several biotech firms to enhance its Research and Development pipeline.

Current affairs also reveal that Merck Group has launched new combination therapies that aim to improve patient outcomes in allergy management. Over the last two years, market valuation has seen a steady increase, attributed to rising allergy prevalence and innovative treatments like sublingual immunotherapy gaining acceptance. The market growth is further fueled by ongoing regulatory support for allergy treatment innovations, indicating a robust future for the Allergy Immunotherapy Market.

Future Outlook

Allergy immunotherapy Market Future Outlook

<p>The Allergy Immunotherapy Market is projected to grow at a 9.43% CAGR from 2025 to 2035, driven by increasing allergy prevalence, technological advancements, and rising consumer awareness.</p>

New opportunities lie in:

  • <p>Development of personalized immunotherapy solutions for specific allergens. Expansion of telehealth platforms for remote allergy consultations. Investment in AI-driven diagnostics for enhanced patient targeting.</p>

<p>By 2035, the market is expected to achieve substantial growth, driven by innovation and increased accessibility.</p>

Market Segmentation

Allergy immunotherapy Market Type Outlook

  • Subcutaneous Immunotherapy
  • Sublingual Immunotherapy
  • Oral Immunotherapy

Allergy immunotherapy Market Product Outlook

  • Allergen Extracts
  • Conventional Immunotherapy
  • Biologics

Allergy immunotherapy Market Indication Outlook

  • Allergic Rhinitis
  • Allergic Asthma
  • Atopic Dermatitis
  • Food Allergies

Allergy immunotherapy Market Patient Type Outlook

  • Pediatric
  • Adult
  • Geriatric

Report Scope

MARKET SIZE 2024 2.83(USD Billion)
MARKET SIZE 2025 3.097(USD Billion)
MARKET SIZE 2035 7.627(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 9.43% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Allergopharma (DE), Anergis (CH), ALK-Abello (DK), Merck Group (DE), Stallergenes Greer (GB), HollisterStier Allergy (US), Circassia Pharmaceuticals (GB), DBV Technologies (FR), Rho (US)
Segments Covered Types, Product, Indication, Patient Type, Regional
Key Market Opportunities Integration of digital health technologies enhances patient engagement in the Allergy Immunotherapy Market.
Key Market Dynamics Rising consumer awareness and regulatory support drive growth in the Allergy Immunotherapy Market, enhancing treatment accessibility.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Allergy Immunotherapy Market as of 2024?

<p>The Allergy Immunotherapy Market was valued at 2.83 USD Billion in 2024.</p>

What is the projected market size for the Allergy Immunotherapy Market by 2035?

<p>The market is projected to reach 7.627 USD Billion by 2035.</p>

What is the expected CAGR for the Allergy Immunotherapy Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the market during the forecast period is 9.43%.</p>

Which segment of the Allergy Immunotherapy Market had the highest valuation in 2024?

<p>In 2024, Sublingual Immunotherapy had the highest valuation at 1.2 USD Billion.</p>

What are the projected values for Subcutaneous Immunotherapy by 2035?

<p>Subcutaneous Immunotherapy is projected to reach 2.25 USD Billion by 2035.</p>

Which product category is expected to grow the most in the Allergy Immunotherapy Market?

<p>Conventional Immunotherapy is anticipated to grow significantly, with a projected value of 3.2 USD Billion by 2035.</p>

What is the market valuation for Allergic Rhinitis in 2024?

<p>Allergic Rhinitis was valued at 1.2 USD Billion in 2024.</p>

How does the market for Adult patients compare to Pediatric patients in 2024?

<p>In 2024, the market for Adult patients was valued at 1.5 USD Billion, compared to 0.85 USD Billion for Pediatric patients.</p>

Which key players are leading the Allergy Immunotherapy Market?

<p>Key players include Allergopharma, Anergis, ALK-Abello, and Merck Group, among others.</p>

What is the projected value for Food Allergies in the Allergy Immunotherapy Market by 2035?

<p>The market for Food Allergies is projected to reach 0.53 USD Billion by 2035.</p>

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Type (USD Billion)
    2. | | 4.1.1 Subcutaneous Immunotherapy
    3. | | 4.1.2 Sublingual Immunotherapy
    4. | | 4.1.3 Oral Immunotherapy
    5. | 4.2 Healthcare, BY Product (USD Billion)
    6. | | 4.2.1 Allergen Extracts
    7. | | 4.2.2 Conventional Immunotherapy
    8. | | 4.2.3 Biologics
    9. | 4.3 Healthcare, BY Indication (USD Billion)
    10. | | 4.3.1 Allergic Rhinitis
    11. | | 4.3.2 Allergic Asthma
    12. | | 4.3.3 Atopic Dermatitis
    13. | | 4.3.4 Food Allergies
    14. | 4.4 Healthcare, BY Patient Type (USD Billion)
    15. | | 4.4.1 Pediatric
    16. | | 4.4.2 Adult
    17. | | 4.4.3 Geriatric
    18. | 4.5 Healthcare, BY Region (USD Billion)
    19. | | 4.5.1 North America
    20. | | | 4.5.1.1 US
    21. | | | 4.5.1.2 Canada
    22. | | 4.5.2 Europe
    23. | | | 4.5.2.1 Germany
    24. | | | 4.5.2.2 UK
    25. | | | 4.5.2.3 France
    26. | | | 4.5.2.4 Russia
    27. | | | 4.5.2.5 Italy
    28. | | | 4.5.2.6 Spain
    29. | | | 4.5.2.7 Rest of Europe
    30. | | 4.5.3 APAC
    31. | | | 4.5.3.1 China
    32. | | | 4.5.3.2 India
    33. | | | 4.5.3.3 Japan
    34. | | | 4.5.3.4 South Korea
    35. | | | 4.5.3.5 Malaysia
    36. | | | 4.5.3.6 Thailand
    37. | | | 4.5.3.7 Indonesia
    38. | | | 4.5.3.8 Rest of APAC
    39. | | 4.5.4 South America
    40. | | | 4.5.4.1 Brazil
    41. | | | 4.5.4.2 Mexico
    42. | | | 4.5.4.3 Argentina
    43. | | | 4.5.4.4 Rest of South America
    44. | | 4.5.5 MEA
    45. | | | 4.5.5.1 GCC Countries
    46. | | | 4.5.5.2 South Africa
    47. | | | 4.5.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Allergopharma (DE)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Anergis (CH)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 ALK-Abello (DK)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Merck Group (DE)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Stallergenes Greer (GB)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 HollisterStier Allergy (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Circassia Pharmaceuticals (GB)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 DBV Technologies (FR)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Rho (US)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY TYPE
    4. | 6.4 US MARKET ANALYSIS BY PRODUCT
    5. | 6.5 US MARKET ANALYSIS BY INDICATION
    6. | 6.6 US MARKET ANALYSIS BY PATIENT TYPE
    7. | 6.7 CANADA MARKET ANALYSIS BY TYPE
    8. | 6.8 CANADA MARKET ANALYSIS BY PRODUCT
    9. | 6.9 CANADA MARKET ANALYSIS BY INDICATION
    10. | 6.10 CANADA MARKET ANALYSIS BY PATIENT TYPE
    11. | 6.11 EUROPE MARKET ANALYSIS
    12. | 6.12 GERMANY MARKET ANALYSIS BY TYPE
    13. | 6.13 GERMANY MARKET ANALYSIS BY PRODUCT
    14. | 6.14 GERMANY MARKET ANALYSIS BY INDICATION
    15. | 6.15 GERMANY MARKET ANALYSIS BY PATIENT TYPE
    16. | 6.16 UK MARKET ANALYSIS BY TYPE
    17. | 6.17 UK MARKET ANALYSIS BY PRODUCT
    18. | 6.18 UK MARKET ANALYSIS BY INDICATION
    19. | 6.19 UK MARKET ANALYSIS BY PATIENT TYPE
    20. | 6.20 FRANCE MARKET ANALYSIS BY TYPE
    21. | 6.21 FRANCE MARKET ANALYSIS BY PRODUCT
    22. | 6.22 FRANCE MARKET ANALYSIS BY INDICATION
    23. | 6.23 FRANCE MARKET ANALYSIS BY PATIENT TYPE
    24. | 6.24 RUSSIA MARKET ANALYSIS BY TYPE
    25. | 6.25 RUSSIA MARKET ANALYSIS BY PRODUCT
    26. | 6.26 RUSSIA MARKET ANALYSIS BY INDICATION
    27. | 6.27 RUSSIA MARKET ANALYSIS BY PATIENT TYPE
    28. | 6.28 ITALY MARKET ANALYSIS BY TYPE
    29. | 6.29 ITALY MARKET ANALYSIS BY PRODUCT
    30. | 6.30 ITALY MARKET ANALYSIS BY INDICATION
    31. | 6.31 ITALY MARKET ANALYSIS BY PATIENT TYPE
    32. | 6.32 SPAIN MARKET ANALYSIS BY TYPE
    33. | 6.33 SPAIN MARKET ANALYSIS BY PRODUCT
    34. | 6.34 SPAIN MARKET ANALYSIS BY INDICATION
    35. | 6.35 SPAIN MARKET ANALYSIS BY PATIENT TYPE
    36. | 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
    37. | 6.37 REST OF EUROPE MARKET ANALYSIS BY PRODUCT
    38. | 6.38 REST OF EUROPE MARKET ANALYSIS BY INDICATION
    39. | 6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT TYPE
    40. | 6.40 APAC MARKET ANALYSIS
    41. | 6.41 CHINA MARKET ANALYSIS BY TYPE
    42. | 6.42 CHINA MARKET ANALYSIS BY PRODUCT
    43. | 6.43 CHINA MARKET ANALYSIS BY INDICATION
    44. | 6.44 CHINA MARKET ANALYSIS BY PATIENT TYPE
    45. | 6.45 INDIA MARKET ANALYSIS BY TYPE
    46. | 6.46 INDIA MARKET ANALYSIS BY PRODUCT
    47. | 6.47 INDIA MARKET ANALYSIS BY INDICATION
    48. | 6.48 INDIA MARKET ANALYSIS BY PATIENT TYPE
    49. | 6.49 JAPAN MARKET ANALYSIS BY TYPE
    50. | 6.50 JAPAN MARKET ANALYSIS BY PRODUCT
    51. | 6.51 JAPAN MARKET ANALYSIS BY INDICATION
    52. | 6.52 JAPAN MARKET ANALYSIS BY PATIENT TYPE
    53. | 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
    54. | 6.54 SOUTH KOREA MARKET ANALYSIS BY PRODUCT
    55. | 6.55 SOUTH KOREA MARKET ANALYSIS BY INDICATION
    56. | 6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT TYPE
    57. | 6.57 MALAYSIA MARKET ANALYSIS BY TYPE
    58. | 6.58 MALAYSIA MARKET ANALYSIS BY PRODUCT
    59. | 6.59 MALAYSIA MARKET ANALYSIS BY INDICATION
    60. | 6.60 MALAYSIA MARKET ANALYSIS BY PATIENT TYPE
    61. | 6.61 THAILAND MARKET ANALYSIS BY TYPE
    62. | 6.62 THAILAND MARKET ANALYSIS BY PRODUCT
    63. | 6.63 THAILAND MARKET ANALYSIS BY INDICATION
    64. | 6.64 THAILAND MARKET ANALYSIS BY PATIENT TYPE
    65. | 6.65 INDONESIA MARKET ANALYSIS BY TYPE
    66. | 6.66 INDONESIA MARKET ANALYSIS BY PRODUCT
    67. | 6.67 INDONESIA MARKET ANALYSIS BY INDICATION
    68. | 6.68 INDONESIA MARKET ANALYSIS BY PATIENT TYPE
    69. | 6.69 REST OF APAC MARKET ANALYSIS BY TYPE
    70. | 6.70 REST OF APAC MARKET ANALYSIS BY PRODUCT
    71. | 6.71 REST OF APAC MARKET ANALYSIS BY INDICATION
    72. | 6.72 REST OF APAC MARKET ANALYSIS BY PATIENT TYPE
    73. | 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. | 6.74 BRAZIL MARKET ANALYSIS BY TYPE
    75. | 6.75 BRAZIL MARKET ANALYSIS BY PRODUCT
    76. | 6.76 BRAZIL MARKET ANALYSIS BY INDICATION
    77. | 6.77 BRAZIL MARKET ANALYSIS BY PATIENT TYPE
    78. | 6.78 MEXICO MARKET ANALYSIS BY TYPE
    79. | 6.79 MEXICO MARKET ANALYSIS BY PRODUCT
    80. | 6.80 MEXICO MARKET ANALYSIS BY INDICATION
    81. | 6.81 MEXICO MARKET ANALYSIS BY PATIENT TYPE
    82. | 6.82 ARGENTINA MARKET ANALYSIS BY TYPE
    83. | 6.83 ARGENTINA MARKET ANALYSIS BY PRODUCT
    84. | 6.84 ARGENTINA MARKET ANALYSIS BY INDICATION
    85. | 6.85 ARGENTINA MARKET ANALYSIS BY PATIENT TYPE
    86. | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
    87. | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT
    88. | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
    89. | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE
    90. | 6.90 MEA MARKET ANALYSIS
    91. | 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
    92. | 6.92 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT
    93. | 6.93 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
    94. | 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT TYPE
    95. | 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
    96. | 6.96 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT
    97. | 6.97 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
    98. | 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT TYPE
    99. | 6.99 REST OF MEA MARKET ANALYSIS BY TYPE
    100. | 6.100 REST OF MEA MARKET ANALYSIS BY PRODUCT
    101. | 6.101 REST OF MEA MARKET ANALYSIS BY INDICATION
    102. | 6.102 REST OF MEA MARKET ANALYSIS BY PATIENT TYPE
    103. | 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. | 6.104 RESEARCH PROCESS OF MRFR
    105. | 6.105 DRO ANALYSIS OF HEALTHCARE
    106. | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. | 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    110. | 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
    111. | 6.111 HEALTHCARE, BY PRODUCT, 2024 (% SHARE)
    112. | 6.112 HEALTHCARE, BY PRODUCT, 2024 TO 2035 (USD Billion)
    113. | 6.113 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
    114. | 6.114 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
    115. | 6.115 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE)
    116. | 6.116 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Billion)
    117. | 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY TYPE, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY PRODUCT, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY INDICATION, 2025-2035 (USD Billion)
    7. | | 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    8. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    9. | | 7.3.1 BY TYPE, 2025-2035 (USD Billion)
    10. | | 7.3.2 BY PRODUCT, 2025-2035 (USD Billion)
    11. | | 7.3.3 BY INDICATION, 2025-2035 (USD Billion)
    12. | | 7.3.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    13. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    14. | | 7.4.1 BY TYPE, 2025-2035 (USD Billion)
    15. | | 7.4.2 BY PRODUCT, 2025-2035 (USD Billion)
    16. | | 7.4.3 BY INDICATION, 2025-2035 (USD Billion)
    17. | | 7.4.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    18. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    19. | | 7.5.1 BY TYPE, 2025-2035 (USD Billion)
    20. | | 7.5.2 BY PRODUCT, 2025-2035 (USD Billion)
    21. | | 7.5.3 BY INDICATION, 2025-2035 (USD Billion)
    22. | | 7.5.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    23. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.6.1 BY TYPE, 2025-2035 (USD Billion)
    25. | | 7.6.2 BY PRODUCT, 2025-2035 (USD Billion)
    26. | | 7.6.3 BY INDICATION, 2025-2035 (USD Billion)
    27. | | 7.6.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    28. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    29. | | 7.7.1 BY TYPE, 2025-2035 (USD Billion)
    30. | | 7.7.2 BY PRODUCT, 2025-2035 (USD Billion)
    31. | | 7.7.3 BY INDICATION, 2025-2035 (USD Billion)
    32. | | 7.7.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    33. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.8.1 BY TYPE, 2025-2035 (USD Billion)
    35. | | 7.8.2 BY PRODUCT, 2025-2035 (USD Billion)
    36. | | 7.8.3 BY INDICATION, 2025-2035 (USD Billion)
    37. | | 7.8.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    38. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    39. | | 7.9.1 BY TYPE, 2025-2035 (USD Billion)
    40. | | 7.9.2 BY PRODUCT, 2025-2035 (USD Billion)
    41. | | 7.9.3 BY INDICATION, 2025-2035 (USD Billion)
    42. | | 7.9.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    43. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.10.1 BY TYPE, 2025-2035 (USD Billion)
    45. | | 7.10.2 BY PRODUCT, 2025-2035 (USD Billion)
    46. | | 7.10.3 BY INDICATION, 2025-2035 (USD Billion)
    47. | | 7.10.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    48. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    49. | | 7.11.1 BY TYPE, 2025-2035 (USD Billion)
    50. | | 7.11.2 BY PRODUCT, 2025-2035 (USD Billion)
    51. | | 7.11.3 BY INDICATION, 2025-2035 (USD Billion)
    52. | | 7.11.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    53. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    54. | | 7.12.1 BY TYPE, 2025-2035 (USD Billion)
    55. | | 7.12.2 BY PRODUCT, 2025-2035 (USD Billion)
    56. | | 7.12.3 BY INDICATION, 2025-2035 (USD Billion)
    57. | | 7.12.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    58. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    59. | | 7.13.1 BY TYPE, 2025-2035 (USD Billion)
    60. | | 7.13.2 BY PRODUCT, 2025-2035 (USD Billion)
    61. | | 7.13.3 BY INDICATION, 2025-2035 (USD Billion)
    62. | | 7.13.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    63. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.14.1 BY TYPE, 2025-2035 (USD Billion)
    65. | | 7.14.2 BY PRODUCT, 2025-2035 (USD Billion)
    66. | | 7.14.3 BY INDICATION, 2025-2035 (USD Billion)
    67. | | 7.14.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    68. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    69. | | 7.15.1 BY TYPE, 2025-2035 (USD Billion)
    70. | | 7.15.2 BY PRODUCT, 2025-2035 (USD Billion)
    71. | | 7.15.3 BY INDICATION, 2025-2035 (USD Billion)
    72. | | 7.15.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    73. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    74. | | 7.16.1 BY TYPE, 2025-2035 (USD Billion)
    75. | | 7.16.2 BY PRODUCT, 2025-2035 (USD Billion)
    76. | | 7.16.3 BY INDICATION, 2025-2035 (USD Billion)
    77. | | 7.16.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    78. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    79. | | 7.17.1 BY TYPE, 2025-2035 (USD Billion)
    80. | | 7.17.2 BY PRODUCT, 2025-2035 (USD Billion)
    81. | | 7.17.3 BY INDICATION, 2025-2035 (USD Billion)
    82. | | 7.17.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    83. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.18.1 BY TYPE, 2025-2035 (USD Billion)
    85. | | 7.18.2 BY PRODUCT, 2025-2035 (USD Billion)
    86. | | 7.18.3 BY INDICATION, 2025-2035 (USD Billion)
    87. | | 7.18.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    88. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    89. | | 7.19.1 BY TYPE, 2025-2035 (USD Billion)
    90. | | 7.19.2 BY PRODUCT, 2025-2035 (USD Billion)
    91. | | 7.19.3 BY INDICATION, 2025-2035 (USD Billion)
    92. | | 7.19.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    93. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.20.1 BY TYPE, 2025-2035 (USD Billion)
    95. | | 7.20.2 BY PRODUCT, 2025-2035 (USD Billion)
    96. | | 7.20.3 BY INDICATION, 2025-2035 (USD Billion)
    97. | | 7.20.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    98. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    99. | | 7.21.1 BY TYPE, 2025-2035 (USD Billion)
    100. | | 7.21.2 BY PRODUCT, 2025-2035 (USD Billion)
    101. | | 7.21.3 BY INDICATION, 2025-2035 (USD Billion)
    102. | | 7.21.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    103. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.22.1 BY TYPE, 2025-2035 (USD Billion)
    105. | | 7.22.2 BY PRODUCT, 2025-2035 (USD Billion)
    106. | | 7.22.3 BY INDICATION, 2025-2035 (USD Billion)
    107. | | 7.22.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    108. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    109. | | 7.23.1 BY TYPE, 2025-2035 (USD Billion)
    110. | | 7.23.2 BY PRODUCT, 2025-2035 (USD Billion)
    111. | | 7.23.3 BY INDICATION, 2025-2035 (USD Billion)
    112. | | 7.23.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    113. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    114. | | 7.24.1 BY TYPE, 2025-2035 (USD Billion)
    115. | | 7.24.2 BY PRODUCT, 2025-2035 (USD Billion)
    116. | | 7.24.3 BY INDICATION, 2025-2035 (USD Billion)
    117. | | 7.24.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    118. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    119. | | 7.25.1 BY TYPE, 2025-2035 (USD Billion)
    120. | | 7.25.2 BY PRODUCT, 2025-2035 (USD Billion)
    121. | | 7.25.3 BY INDICATION, 2025-2035 (USD Billion)
    122. | | 7.25.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    123. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.26.1 BY TYPE, 2025-2035 (USD Billion)
    125. | | 7.26.2 BY PRODUCT, 2025-2035 (USD Billion)
    126. | | 7.26.3 BY INDICATION, 2025-2035 (USD Billion)
    127. | | 7.26.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    128. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    129. | | 7.27.1 BY TYPE, 2025-2035 (USD Billion)
    130. | | 7.27.2 BY PRODUCT, 2025-2035 (USD Billion)
    131. | | 7.27.3 BY INDICATION, 2025-2035 (USD Billion)
    132. | | 7.27.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    133. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    134. | | 7.28.1 BY TYPE, 2025-2035 (USD Billion)
    135. | | 7.28.2 BY PRODUCT, 2025-2035 (USD Billion)
    136. | | 7.28.3 BY INDICATION, 2025-2035 (USD Billion)
    137. | | 7.28.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    138. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    139. | | 7.29.1 BY TYPE, 2025-2035 (USD Billion)
    140. | | 7.29.2 BY PRODUCT, 2025-2035 (USD Billion)
    141. | | 7.29.3 BY INDICATION, 2025-2035 (USD Billion)
    142. | | 7.29.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    143. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    144. | | 7.30.1 BY TYPE, 2025-2035 (USD Billion)
    145. | | 7.30.2 BY PRODUCT, 2025-2035 (USD Billion)
    146. | | 7.30.3 BY INDICATION, 2025-2035 (USD Billion)
    147. | | 7.30.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
    148. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    149. | | 7.31.1
    150. | 7.32 ACQUISITION/PARTNERSHIP
    151. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • Subcutaneous Immunotherapy
  • Sublingual Immunotherapy
  • Oral Immunotherapy

Healthcare By Product (USD Billion, 2025-2035)

  • Allergen Extracts
  • Conventional Immunotherapy
  • Biologics

Healthcare By Indication (USD Billion, 2025-2035)

  • Allergic Rhinitis
  • Allergic Asthma
  • Atopic Dermatitis
  • Food Allergies

Healthcare By Patient Type (USD Billion, 2025-2035)

  • Pediatric
  • Adult
  • Geriatric
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓
%>